REGULAR CONTENT
Final ID
623
Type
Educational Exhibit-Poster Only
Authors
R Gaba1, R Schwind2, S Ballet3
Institutions
1University of Illinois Hospital, Chicago, IL, 2University of Illinois Cancer Center, Chicago, IL, 3Guerbet, Villepinte, France
Purpose
c-TACE is a therapeutic mainstay for liver cancer. Even so, knowledge of the safety/efficacy of Lipiodol®-based LRTs in animal liver cancer models is critical to developing novel LRT approaches, using Lipiodol® with new anticancer agents and precision therapies. This study systemically reviewed the pharmacokinetics (PK), safety, and efficacy of Lipiodol®-based LRTs for liver cancer in preclinical models.
Materials & Methods
A MEDLINE search was performed from 1988-2016. Terms included: hepatocellular carcinoma, HCC, liver cell carcinoma, liver or hepatic, or hepatocarcinoma; transarterial or chemoembolization or TACE; animal; Lipiodol, Ethiodol, iodized oil, or poppy-seed oil. Inclusion criteria spanned: peer-reviewed journal, accepted animal model, safety/efficacy data reported. Exclusion criteria were: inadequate safety/efficacy data, anticancer drug name/dose not available, article not in English. Outcomes included drug uptake in tumor, PK/tolerance, tumor response, and survival.
Results
Of 114 identified articles, 54 (47%) met inclusion criteria. Three, 2, 19, 27, and 3 articles used cell line, mice, rat, rabbit, and pig models. 21 papers reported drug uptake, PK, and tolerance data, showing 0.5-9.5% injected chemo dose (mainly dox/epirubicin) in tumor. Tumor-to-normal liver drug distribution ratio ranged from 2-157. Toxicology data showed transient serum liver lab elevation 1-day post-LRT. There was no noteworthy liver or extra-hepatic histologic damage. 11 articles reported tumor response (9 Lipiodol®/chemo and 2 Lipiodol®/Re-188), and showed 0-30% viable tumor and –10% to –34% tumor growth 7-days post-LRT. 2 articles reported survival (Lipiodol®+epirubicin/Re-188 in rats), showing significantly longer survival post-LRT vs. untreated controls (56/60 days vs. 33/28 days). 14 articles described Lipiodol® mixed with radiopharmaceutical (7 papers) or novel immune (2 papers), anti-angiogenic (5 papers), and gene (5 papers) therapies.
Conclusions
c-TACE animal studies show preferential tumor uptake of anticancer agent, good hepatic/systemic tolerance, high response, and enhanced survival after Lipiodol® LRT. Innovative Lipiodol®-based LRTs can be evaluated with animal models and translational techniques.
Final ID
623
Type
Educational Exhibit-Poster Only
Authors
R Gaba1, R Schwind2, S Ballet3
Institutions
1University of Illinois Hospital, Chicago, IL, 2University of Illinois Cancer Center, Chicago, IL, 3Guerbet, Villepinte, France
Purpose
c-TACE is a therapeutic mainstay for liver cancer. Even so, knowledge of the safety/efficacy of Lipiodol®-based LRTs in animal liver cancer models is critical to developing novel LRT approaches, using Lipiodol® with new anticancer agents and precision therapies. This study systemically reviewed the pharmacokinetics (PK), safety, and efficacy of Lipiodol®-based LRTs for liver cancer in preclinical models.
Materials & Methods
A MEDLINE search was performed from 1988-2016. Terms included: hepatocellular carcinoma, HCC, liver cell carcinoma, liver or hepatic, or hepatocarcinoma; transarterial or chemoembolization or TACE; animal; Lipiodol, Ethiodol, iodized oil, or poppy-seed oil. Inclusion criteria spanned: peer-reviewed journal, accepted animal model, safety/efficacy data reported. Exclusion criteria were: inadequate safety/efficacy data, anticancer drug name/dose not available, article not in English. Outcomes included drug uptake in tumor, PK/tolerance, tumor response, and survival.
Results
Of 114 identified articles, 54 (47%) met inclusion criteria. Three, 2, 19, 27, and 3 articles used cell line, mice, rat, rabbit, and pig models. 21 papers reported drug uptake, PK, and tolerance data, showing 0.5-9.5% injected chemo dose (mainly dox/epirubicin) in tumor. Tumor-to-normal liver drug distribution ratio ranged from 2-157. Toxicology data showed transient serum liver lab elevation 1-day post-LRT. There was no noteworthy liver or extra-hepatic histologic damage. 11 articles reported tumor response (9 Lipiodol®/chemo and 2 Lipiodol®/Re-188), and showed 0-30% viable tumor and –10% to –34% tumor growth 7-days post-LRT. 2 articles reported survival (Lipiodol®+epirubicin/Re-188 in rats), showing significantly longer survival post-LRT vs. untreated controls (56/60 days vs. 33/28 days). 14 articles described Lipiodol® mixed with radiopharmaceutical (7 papers) or novel immune (2 papers), anti-angiogenic (5 papers), and gene (5 papers) therapies.
Conclusions
c-TACE animal studies show preferential tumor uptake of anticancer agent, good hepatic/systemic tolerance, high response, and enhanced survival after Lipiodol® LRT. Innovative Lipiodol®-based LRTs can be evaluated with animal models and translational techniques.